Results 111 to 120 of about 473,506 (307)

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Genome Editing of the Octoplid Fragaria x ananassa Using the CRISPR/Cas9 System

, 2017
Gene functional analyses in the cultivated strawberry (Fragaria × ananassa) are commonly carried out via gene silencing using intron hairpin RNA (ihpRNA)-based constructs. However, this system is not always as efficient or stable as expected.
Posé-Padilla, David, Posé Padilla, David, Martín-Pizarro, Carmen   +2 more
core  

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Platelet-specific P2Y1 receptor deficient mice have suppressed pulmonary leukocyte recruitment in response to lipopolysaccharide

Respiratory Research
A role for the P2Y1 receptor (P2Y1R) in platelet-driven inflammation has been established using a pharmacological approach, limited to an acute 4 h time span.
Dingxin Pan, Alembert Lino-Alvarado, Richard T. Amison, Tolga Oralman, Reah Evans, Oliver Baker, Graham Cocks, Clive P. Page, Simon C. Pitchford   +8 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Genome editing in rice [PDF]

Rice, 2020
Masaki Endo, Seiichi Toki
openaire   +3 more sources

CRISPR/Cas9-mediated genome editing in naïve human embryonic stem cells

, 2017
The combination of genome-edited human embryonic stem cells (hESCs) and subsequent neural differentiation is a powerful tool to study neurodevelopmental disorders.
Menten, Björn, Eva D’haene, Van der Jeught, Margot, Björn Menten, Van der Jeught, MargotUGent00200418338180200071288397209273771503A0AEC2-F0EE-11E1-A9DE-61C894A0A6B4, Heindryckx, BjörnGE38UZGent0019942807928010013427010000-0003-0630-8420F5C0698C-F0ED-11E1-A9DE-61C894A0A6B4, Lies Vantomme, Jacobs, Eva0000902820418020019124519780165626731EDDAD52-F0EE-11E1-A9DE-61C894A0A6B4, Vergult, SarahGE310020030773798020004217820000-0002-0816-6262FB499586-F0ED-11E1-A9DE-61C894A0A6B4, Jacobs, Eva, Vantomme, Lies, Volders, Pieter-JanGE310000806654028020010680460000-0002-2685-2637153408B4-F0EE-11E1-A9DE-61C894A0A6B4, Eva Z. Jacobs, Menten, BjörnGE31UZGent0019961997768010017113010000-0001-8182-659XF6A4B240-F0ED-11E1-A9DE-61C894A0A6B4, Sarah Vergult, D'haene, Eva, Margot Van der Jeught, Pieter-Jan Volders, Eva Van Lombergen, Volders, Pieter-Jan, Vantomme, LiesGE31802000063387F87548E6-F0ED-11E1-A9DE-61C894A0A6B4, Sharat Warrier, D'haene, EvaGE310001007992658020021130208020021160500000-0002-5936-82942F962566-F0EE-11E1-A9DE-61C894A0A6B4, Vergult, Sarah, Warrier, Sharat, Van Lombergen, Eva, Björn Heindryckx, Vanlombergen, Eva, Warrier, Sharat000120899180802001340757973042502303382D65D8-18A6-11E2-AE0F-28CF10BDE39D, Heindryckx, Björn   +29 more
core   +1 more source

Pan-cancer analysis identifies CD155 as a promising target for CAR-T cell therapy

Genome Medicine
Background Chimeric antigen receptor T (CAR-T) cell therapy has shown remarkable success in treating hematologic malignancies. However, its efficacy against solid tumors remains limited. One of the major challenges is the lack of specific tumor antigens.
Xiaohong Liu, Yue Sun, Boxu Lin, Hao Xiong, Xinyue Lu, Binghe Tan, Chenglin Zhang, Mingyao Liu, Juliang Qin, Na Zhang, Bing Du   +10 more
doaj   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Genome Editing for Low-Acrylamide Wheat [PDF]

, 2020
Acrylamide (C3H5NO) is a food processing contaminant that has been classed as a probable (Group 2a) human carcinogen. Acrylamide forms from the reaction of free (non-protein) asparagine with reducing sugars during food processing.
Raffan, S., Raffan, Sarah
core